Skip to main content

Advertisement

SpringerLink
Log in

Miliary tuberculosis after initiation of ibrutinib in chronic lymphocytic leukemia

  • Letter to the Editor
  • Published:
Annals of Hematology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Nabhan C, Rosen ST (2014) Chronic lymphocytic leukemia: a clinical review. JAMA 312:2265–2276

    Article  PubMed  Google Scholar 

  2. Byrd JC, Furman RR, Coutre SE et al (2013) Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med 369:32–42

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  3. Wang ML, Rule S, Martin P et al (2013) Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med 369:507–516

    Article  CAS  PubMed  Google Scholar 

  4. Byrd JC, Brown JR, O’Brien S et al (2014) Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med 371:213–223

    Article  PubMed Central  PubMed  Google Scholar 

  5. Byrd JC, Furman RR, Coutre SE et al (2015) Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib. Blood [Internet] Available from: http://www.bloodjournal.org/content/early/2015/02/23/blood-2014-10-606038 [cited 2015 Mar 23]

  6. Burger JA, Gribben JG (2014) The microenvironment in chronic lymphocytic leukemia (CLL) and other B cell malignancies: insight into disease biology and new targeted therapies. Semin Cancer Biol 24:71–81

    Article  CAS  PubMed  Google Scholar 

  7. Al-Anazi KA, Al-Jasser AM, Alsaleh K (2014) Infections caused by mycobacterium tuberculosis in recipients of hematopoietic stem cell transplantation. Front Oncol. doi:10.3389/fonc.2014.00231

    Google Scholar 

  8. Dubovsky JA, Beckwith KA, Natarajan G et al (2013) Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes. Blood 122:2539–2549

    Article  CAS  PubMed Central  PubMed  Google Scholar 

Download references

Conflict of interest

No conflict of interest is declared.

Author information

Author notes

    Authors and Affiliations

    1. Division of Hematology and Oncology, University Hospital of Leipzig, 04103, Leipzig, Germany

      Song-Yau Wang, Thomas Ebert, Nadja Jaekel, Dietger Niederwieser & Haifa Kathrin Al-Ali

    2. Department of Endocrinology and Nephrology, University Hospital of Leipzig, 04103, Leipzig, Germany

      Thomas Ebert

    3. Division of Infectious Diseases and Tropical Medicine, Department of Gastroenterology and Rheumatology, University Hospital of Leipzig, 04103, Leipzig, Germany

      Stefan Schubert

    4. Division of Hematology and Oncology, University of Leipzig, Johannisallee 32A, Leipzig, 04103, Germany

      Haifa Kathrin Al-Ali

    Authors
    1. Song-Yau Wang
      View author publications

      You can also search for this author in PubMed Google Scholar

    2. Thomas Ebert
      View author publications

      You can also search for this author in PubMed Google Scholar

    3. Nadja Jaekel
      View author publications

      You can also search for this author in PubMed Google Scholar

    4. Stefan Schubert
      View author publications

      You can also search for this author in PubMed Google Scholar

    5. Dietger Niederwieser
      View author publications

      You can also search for this author in PubMed Google Scholar

    6. Haifa Kathrin Al-Ali
      View author publications

      You can also search for this author in PubMed Google Scholar

    Corresponding author

    Correspondence to Haifa Kathrin Al-Ali.

    Additional information

    Song-Yau Wang and Thomas Ebert contributed equally to this work.

    Rights and permissions

    Reprints and permissions

    About this article

    Check for updates. Verify currency and authenticity via CrossMark

    Cite this article

    Wang, SY., Ebert, T., Jaekel, N. et al. Miliary tuberculosis after initiation of ibrutinib in chronic lymphocytic leukemia. Ann Hematol 94, 1419–1420 (2015). https://doi.org/10.1007/s00277-015-2385-0

    Download citation

    • Received:

    • Accepted:

    • Published:

    • Issue Date:

    • DOI: https://doi.org/10.1007/s00277-015-2385-0

    Keywords

    Search

    Navigation